1 / 19

March 31, 2009

Diagnostics Policy Issues Update Khatereh Calleja Associate Vice President Technology and Regulatory Affairs. March 31, 2009. Presentation Outline. Current Environment/Role for Diagnostics General Legislative Landscape Key Regulatory Issues

dmatthew
Download Presentation

March 31, 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Diagnostics PolicyIssues UpdateKhatereh CallejaAssociate Vice PresidentTechnology and Regulatory Affairs March 31, 2009

  2. Presentation Outline • Current Environment/Role for Diagnostics • General Legislative Landscape • Key Regulatory Issues • Other Policy Issues (Personalized Medicine, Companion Diagnostics)

  3. Diagnostics Are Well-Positioned in the Current Environment • Innovation - Diagnostics are evolving to enable more sensitive and specific detection of disease at earlier stages than ever before • Low Cost – Diagnostics account for less than 2% of all Medicare spending, but influence up to 70% of all health care decisions • Underutilized - Standard of care diagnostics are underused 51% of the time, according to the Rand Corp.

  4. Legislative Landscape: 111th Congress Early Priorities • Jobs and Economic Recovery (Stimulus) • Aid to States, Comparative Effectiveness Research, Health IT • Stimulus package is now law but more is expected • Other Key issues for this year • Energy/Global Warming, Health Reform, Financial services/financial market reform/housing • Tasks Related to a New Administration • Approve Cabinet nominations and other key personnel • President’s budget outline released—awaiting more detailed info

  5. Diagnostics Legislation—A Look Back • Longstanding effort to reform payment system for diagnostics • Advanced Laboratory Diagnostics Act (ALDA) • Introduced in 109th and 110th Congresses • Demo to evaluate a new Medicare payment system for molecular diagnostics • Repeal of Lab Competitive Bidding Demo—in July 2008 Medicare bill • Genomics and Personalized Medicine Act • Obama/Burr-Cosponsors in Senate • Laboratory Test Improvement Act

  6. Health Reform and Potential Role for Diagnostics • Senate is leading the way • June mark-up likely—floor action anticipated before August recess • White House is increasingly focused on health care reform • Key goals in Health Reform • Improve quality and efficiency; reduce cost (waste) • Diagnostics can play a key role—potential opportunity • Unlock the potential of personalized medicine

  7. Health Reform—Potential Concepts for Diagnostic Payment Reform • Improve existing processes for establishing payment rates for new tests (gap-fill, crosswalk) • Pursue improved, new pathway for establishing payment • Current discussions taking place with stakeholders • Administrative (non-legislative) reform also being sought

  8. Health Reform—Other Issues to Watch • Comparative effectiveness research • Diagnostics within the scope: concerns about evidence expectations • Potential use of diagnostics in research about other products • Diagnostics as a “pay-for”? • Achieving universal coverage will be expensive • Defense: possible cuts to Medicare’s clinical lab fee schedule?

  9. Diagnostic Regulatory Prioritiesat a Glance

  10. AdvaMed’s Risk-Based Approach for Regulation of All Diagnostics • Modernized approach to diagnostics regulation • Supports timely patient access to all safe and effective diagnostics • Based in FDA triage decision model and 1997 FDA Modernization Act requirement for “least burdensome” • Includes consideration of class I/II IVDs for exemption (MDUFMA qualitatative goal)

  11. AdvaMed’s Risk-Based Approach for Regulation of All Diagnostics • Re-align intensity of regulatory oversight commensurate with patient risk • Focus FDA resources on high risk products • Exempt low risk diagnostic tests from premarket submission—Class I/IIIVD Candidates for potential exemption to be submitted to FDA this year • Apply risk-based approach to all diagnostic tests, regardless of where they are produced

  12. AdvaMed’s Risk-Based Approach for Regulation of All Diagnostics • Adds objective, transparent, and standardized criteria/process(es) for stratifying pre-market regulatory data requirements • Considers clinical risk and availability of mitigations

  13. Balancing Act—Potential Considerations Reduction/Mitigation associated w. -Scientific evidence -General and special controls -Laboratory process controls -User experience Risk associated w. -Clinical use of test -Novelty of analyte -Novelty of technology -Training of operator

  14. Applying the Risk-Based Approach • Use tier triage decision model • Consider novelty of analyte, novelty of technology, clinical use of test, and training/ experience of operator • Consider risk mitigation factors • Assignment of a tier

  15. Other Key MDUFMA-RelatedActivities • Pre-IDE Process ImprovementDevelopment of Industry Best Practices proposal for incorporation into guidance: • Meeting documentation/record • Time frame for action • Consistency in use of guidance documents • Information/context necessary for specific questions • Communication of rationale for change • Process for resolving comments/disagreements

  16. Other Key MDUFMA-RelatedActivities • CLIA Waiver Process Improvement for POC Tests • Clarification via guidance on various issues • mimic intended use population, waiver operators/not trained tech, recommend to run 510(k) and CLIA studies separately, etc. • Ongoing discussion re. qualitative cut off studies and other areas in CLIA waiver guidance • Differences in regulatory authority/interpretation of CLIA regulations

  17. Molecular Diagnostics and Companion Drug-Diagnostics • FDA working to publish revised drug-diagnostic co-development guidance—to clarify regulatory requirement • FDA focus on key role of companion diagnostic development (rather than codevelopment) • Recognition that one size of evidence will not fit all

  18. Personalized Medicine Clearly A Priority • CDRH Matrix-Diagnostics and Personalized Medicine Network • FDA OIVD—Expanding Staff to support Personalized Medicine • New Senior Genomics Advisor in Office of Chief Scientist

  19. Challenges, but Many Opportunities • Regulatory and reimbursement should encourage innovation • Current environment--Overall focus on promotion of personalized medicine and health care reform • Clear opportunities for diagnostics

More Related